Edward Sausville
Medical Oncology
Credentials: · · ·
History
- 1982–1984
Medical Oncology
- 1979–1982
Internal Medicine
1975–1979
Research
Proteasome inhibitors: a novel class of potent and effective antitumor agents
Cancer Research · 1999 · 1,239 citations
Cancer Research · 1998 · 1,101 citations
A gene expression database for the molecular pharmacology of cancer
Nature Genetics · 2000 · 1,034 citations
- AS
41 papers
William Figg
30 papers
- JB
16 papers
15 papers
13 papers
- RM
12 papers
- GM
11 papers
11 papers
Grants
- 2015–2017
Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors
National Cancer Institute · R44
PI · $1.1M · Keystone Nano, Inc.
- 2008–2016
UMGCC Paul Calabresi Clinical Oncology Training Program
National Cancer Institute · K12
Contact PI · $4M · University of Maryland Baltimore
- 2008–2013
Treatment of Melanoma with Wild-Type P53 and Detectable S100B Using Pentamidine:
National Cancer Institute · R21
Contact PI · $622.5K · University of Maryland Baltimore
- 2008–2011
University of Maryland Greenebaum Cancer Centersupport Grant
National Cancer Institute · P30
Project lead · $1.1M · University of Maryland Baltimore
Clinical trials
- 2017–2023
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Keystone Nano, Inc
- 2011
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Mersana Therapeutics
- 2010–2013
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Mersana Therapeutics
- 2008–2012
0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma
Principal investigator · Terminated · Phase 2
University of Maryland, Baltimore